Niraparix — Niraparib 100 mg capsule
Order Now
Rx Niraparib 100 mg capsules · once daily

Niraparix

Niraparib INN · 100 mg capsule

Precision PARP inhibition for ovarian cancer maintenance

The first and only once-daily oral PARP inhibitor for maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer after response to platinum-based chemotherapy.

Order Now Prescribing Information
Dose
300 mg
Frequency
1× daily
Per pot
90 caps
Niraparix 100 mg carton and 90-capsule pot
Once daily
3 × 100 mg
Target
PARP-1 / PARP-2
ONCE DAILY • ORAL • PARP INHIBITOR •
PARP inhibitorOnce-daily oralMaintenance therapyRecurrent ovarian cancerFallopian tube cancerPrimary peritoneal cancer90 capsules · HDPE potBeacon Pharmaceuticals PLCPARP inhibitorOnce-daily oralMaintenance therapyRecurrent ovarian cancerFallopian tube cancerPrimary peritoneal cancer90 capsules · HDPE potBeacon Pharmaceuticals PLC
Niraparix

Niraparib INN

PARP inhibitor (oncology)

Niraparib structural formula
C19H20N4O·Indazole-carboxamide·Oral
About Niraparix

Niraparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Niraparix is a once-daily, oral medicine used when the cancer comes back — the first and only once-daily PARP inhibitor used after the cancer has responded (complete or partial response) to platinum-based chemotherapy.

Learn more
Quality-assured oncology

Niraparix — quality-assured Niraparib for ovarian cancer maintenance

Manufactured by Beacon Pharmaceuticals PLC in dedicated oncology facilities, Niraparix gives patients, doctors and distributors a dependable once-daily PARP inhibitor with clear, label-based product information.

01

Once-daily oral

300 mg (three 100 mg capsules) taken once daily, with or without food.

02

First once-daily PARP inhibitor

The first and only once-daily PARP inhibitor used after platinum-based chemotherapy.

03

Ovarian · fallopian · peritoneal

Maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.

04

After platinum response

For patients in a complete or partial response to platinum-based chemotherapy.

05

Start within 8 weeks

Begin no later than 8 weeks after the most recent platinum-containing regimen.

06

Beacon Pharmaceuticals PLC

Manufactured to international quality standards.

Indications

Conditions treated

Niraparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

All indications
01 / 03

Epithelial Ovarian Cancer

The most common form of ovarian cancer, arising from the cells that cover the ovary. Niraparix is used as maintenance after the cancer has responded to platinum chemotherapy.
02 / 03

Fallopian Tube Cancer

Cancer that begins in the tubes connecting the ovaries to the uterus. It behaves and is treated much like epithelial ovarian cancer.
03 / 03

Primary Peritoneal Cancer

Cancer of the peritoneum — the thin lining of the abdomen. It closely resembles epithelial ovarian cancer and shares its treatment approach.
Mechanism of action

How PARP inhibition works

Niraparib is an inhibitor of the PARP-1 and PARP-2 enzymes, which play a role in DNA repair. Follow the simplified animation below.

  1. 01

    DNA damage

    Cancer cells constantly acquire single-strand breaks in their DNA.

  2. 02

    PARP repairs the break

    PARP-1 / PARP-2 enzymes bind the break and recruit repair machinery.

  3. 03

    Niraparib traps PARP

    Niraparib blocks PARP activity and locks PARP–DNA complexes in place.

  4. 04

    Cancer cell death

    Unrepaired damage accumulates, leading to DNA damage, apoptosis and cell death.

CANCER CELL · NUCLEUS Strand break PARP Repair recruited ↻ Niraparib binds LOCKED DNA damage → apoptosis

Simplified illustration for educational purposes.

Dosing & administration

Simple, once-daily dosing

The recommended dose of Niraparib as monotherapy is 300 mg — three 100 mg capsules taken orally once daily.

  • Same time each day

    Take the dose at approximately the same time every day.

  • Swallow whole

    Each capsule should be swallowed whole.

  • With or without food

    Niraparib may be taken with or without food.

  • Bedtime may help nausea

    Bedtime administration may be a potential method for managing nausea.

  • Start within 8 weeks

    Begin no later than 8 weeks after the most recent platinum-containing regimen.

300 mg
3 × 100 mg · once daily
every 24 hours
Missed dose?
Take the next one on schedule
Continue
Until progression or toxicity
A woman enjoying the outdoors at sunrise
Once-daily,
at home
For patients

Benefits & support

Niraparix aims to make maintenance treatment easier for women living with recurrent ovarian, fallopian tube or primary peritoneal cancer. A single daily dose of three capsules, taken with or without food, fits into everyday life at home.

Patients can request product details or speak with their oncologist about whether Niraparix is right for them. Our team is committed to clear information and safe, verified access.

  • Once-daily oral dosing
  • Clear dosing guidance
  • Authentic, QR-verified packs
  • Responsive support team
Beacon quality-control laboratory
Product sheets
& clinical data
For healthcare professionals

For clinicians & distributors

Beacon supplies Niraparix to hospitals, oncology clinics, pharmacies and international distributors, with steady inventory and fast response times.

Healthcare teams can access the prescribing information, dosing guidance and safety monitoring requirements to support clinical decisions. We welcome long-term partnerships.

Prescribing information Download PDF
Worldwide access

Global Patient Support Program

Life-saving oncology medicines are either beyond the reach of general people or unavailable in many countries. Because of the patent exemptions for Bangladeshi companies, Beacon Pharmaceuticals can manufacture patented medicines to support patients worldwide.

Global shipping
Verified supply
Reliable delivery
Global shipment by air, sea and road
FAQ

Frequently asked questions

Quick answers about Niraparix. For clinical questions, always consult the treating oncologist.

View all FAQs

Niraparix (niraparib) is a cancer medicine supplied as 100 mg capsules — 90 capsules per HDPE pot. It is the first and only once-daily oral PARP inhibitor.

Niraparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

The recommended dose is 300 mg (three 100 mg capsules) taken orally once daily, at about the same time each day. Capsules should be swallowed whole and may be taken with or without food; bedtime administration may help manage nausea.

Patients should start no later than 8 weeks after their most recent platinum-containing regimen. Treatment should continue until disease progression or unacceptable toxicity.

In the case of a missed dose, patients should take their next dose at its regularly scheduled time (do not take a double dose).

Get in touch

Request Niraparix today

Place a product request online or reach our team — we will confirm availability and delivery details with you.

Order Now Talk to us